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S olid pancreatic masses occur for many reasons [1].  Therefore,  accurate histological diagnosis 
is essential for precise diagnosis and treatment.
　 Endoscopic ultrasound-guided ﬁne needle aspira-
tion (EUS-FNA) has become the standard procedure 
for sampling solid pancreatic masses [2].  EUS-FNA 
is performed with 19- to 25-gauge needles [3-5].  
EUS-FNA with 25-gauge needles achieves a higher 
technical success rate than other needles.  However,  
an adequate specimen for histological diagnosis some-
times cannot be obtained,  especially from neuroendo-
crine tumors (NET),  solid pseudo papillary neoplasms 
(SPN),  malignant lymphoma,  and benign inﬂammatory 
lesions such as tumor-forming pancreatitis and autoim-
mune pancreatitis [2].  This is sometimes the case 
even with the 19-gauge needles [5,6]; some lesions,  
such as the head of pancreas,  are diﬃcult to puncture 
with 19-gauge needles.  On the other hand,  22-gauge 
needles can puncture a wider variety of lesions [7] 
and are commonly used in clinical practice.
　 Recently,  various needles have been developed to 
obtain a greater amount of tissue and achieve a more 
accurate diagnostic rate [8].  EUS Sonopsy CY® is a 
newly designed ultrasonographic biopsy aspiration 
needle.  This needle features the Menghini Type 
Needle Tip biopsy system,  an outer needle shape suit-
able for a biopsy,  and good supersonic wave depiction 
characteristics.  In this biopsy system,  the inner nee-
dle remains inside the outer needle during aspiration 
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so it can obtain suﬃcient good-quality tissue without 
crushing the tissue.  Furthermore,  owing to the 
tapered bevel edge,  tissue can be taken in the outer 
needle,  and we postulate that EUS Sonopsy CY® can 
achieve a greater amount of appropriate tissue collec-
tion for diagnosis.  We have initiated a prospective,  
randomized,  controlled study to determine the diag-
nostic accuracy of this modality.
Endpoints
　 The primary outcome is the tissue collection rate.  
The secondary outcome is the tissue collection rate of 
the 2 punctures in terms of tumor size,  location,  
puncture route,  tissue diagnosis rate,  and adverse 
events.
Eligibility Criteria
　 All patients who meet the inclusion and exclusion 
criteria listed in Table 1,  Table 2 will be invited.  An 
investigator will obtain written informed consent from 
each patient before any screening or inclusion proce-
dure.
　 This study was conducted in compliance with the 
principles of the Declaration of Helsinki,  and the pro-
tocol was approved by the ethics committee of 
Okayama University Hospital (No1601-003).  This 
study was registered with the University Hospital 
Medical Information Network Clinical Trials Registry 
(UMIN 000020668).
Treatment Methods
　 Study design. This is a prospective,  single- 
blind,  randomized,  controlled trial to investigate 
which needle can obtain the greatest amount of suit-
able tissue for histological diagnosis in EUS-FNA,  
the EUS Sonopsy CY® (HAKKO,  Ngano,  Japan) or a 
conventional needle (Sonotip® 22G; Medicos Hirata,  
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Table 2　 ECOG Performance Status
GRADE
0 Fully active,  able to carry on all pre-disease performance without restriction
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature,  e.g.,  light 
house work,  oﬃce work
2 Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking 
hours
3 Capable of only limited selfcare; conﬁned to bed or chair more than 50% of waking hours
4 Completely disabled; cannot carry on any selfcare; totally conﬁned to bed or chair
5 Dead
ECOG,  Eastern Cooperative Oncology Group.
Table 1　 The inclusion and exclusion criteria
The inclusion criteria
Patients with pancreatic mass who are refered to EUS-FNA
The exclusion criteria
Patients with Performance status 4 ,5 (ECOG) (Table 2)
Patients who have risk of bleeding,  or patients with platelet count less than 50,000/mm2
Patients with antithrombotic agent 2 agent or more
Patients with pancreatic mass which we cannot detect by EUS
Pregnant woman
Patients less than 20 years old
Patients who do not agree to participate in this study
Patients who determined to be inappropriate
EUS-FNA,  endoscopic ultrasonography-guided ﬁne needle aspiration; EUS,  endoscopic ultrasonography; ECOG,  Eastern Cooperative 
Oncology Group.
Tokyo,  Japan).
　 Intervention. Patients with solid pancreatic 
masses detected by ultrasonography,  computed tomog-
raphy,  or magnetic resonance imaging will be enrolled 
in this study.
　 For each lesion,  2 needle punctures will be per-
formed with EUS Sonopsy CY® (needle S) and a con-
ventional needle (Sonotip® 22-gauge [needle N]).  The 
procedures are randomly set in one of 2 patterns:  
(1) needle S followed by needle N (Group S) and 
(2) needle N followed by needle S (Group N).
　 All procedures will be performed by an experi-
enced endo-sonographer who has performed more than 
50 procedures over the past year or 100 procedures 
in total.  Patients will be placed in the left lateral 
decubitus position and will be administered conscious 
sedation with intravenous midazolam and pethidine.  
EUS and EUS-FNA will be performed with a curved 
linear array echo-endoscope (GF-UCT-260-AL5;  
OLYMPUS Medical System,  Tokyo,  Japan).  The 
puncture with needle S will be performed as follows:  
After puncturing the mass,  we will draw back the 
aspiration piston to the locking position.  After waiting 
for more than 3 sec until negative pressure becomes 
active at the needle tip,  we will push forward the 
puncture needle several times to pass the target lesion.  
After removing the outer puncture needle from the 
protective tube,  we will attach a syringe to the proxi-
mal end of the outer barrel and then push tissue pieces 
from the outer puncture needle with saline.  The punc-
ture with needle N will be performed as fol-
lows: After we puncture the mass,  the stylet will be 
withdrawn.  An accessory syringe will be attached to 
the proximal end of the needle.  The needle will then 
be moved back and forth 10 times while performing 
suction [3,4].  Tissue material will be expressed onto 
the slides by loading the stylet into the needle assem-
bly.  Obtained samples will be categorized according 
to needle type and ﬁxed with formalin for histological 
examination.  Rapid on-site evaluation will be per-
formed at all institutions.  If adequate samples are not 
obtained during the two punctures,  additional punc-
tures will be permitted (Fig.  1).
　 Randomization. After conﬁrming fulﬁllment 
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Patients with solid pancreatic masses
EUS
Randomly set in either of 2 patterns
Needle S puncture ﬁrst group
（Group S）
Needle S 　 Needle N
Needle N puncture ﬁrst group
（Group N）
Needle N 　 Needle S
If the adequate samples are not obtained during the 2 punctures, 
an additional punctures are permitted.
Fig. 1　 Study ﬂow
of the eligibility criteria,  registration will be made via 
a web-based system to the data center.  Patients will 
be randomized to either Group S or Group N by a 
blocked randomization method,  balancing the arms 
with age,  sex (male vs.  female),  and lesion (the head 
of the pancreas vs.  the body and tail of the pancreas).
Statistical Consideration
　 The primary endpoint is obtaining adequate speci-
mens for histological diagnosis on the ﬁrst puncture in 
each group.  The adequacy of samples will be evalu-
ated by an experienced pathologist using the 
Cellularity scoring system [9] as follows: Score 0:  
Insufﬁcient material for interpretation,  Score 1:  
Sufﬁcient material for limited cytological inter-
pretation,  probably not representative,  Score 2:  
Sufﬁcient material for adequate cytological interpre-
tation,  Score 3: Sufﬁcient material for limited histo-
logical interpretation,  Score 4: Sufﬁcient material 
for adequate histological interpretation,  low quality 
(total material＜1×10 power ﬁeld in length),  Score 
5: Sufﬁcient material for adequate histological inter-
pretation,  high quality (＞1×10 power ﬁeld in 
length).  In this study,  a sample with a score of 3-5 is 
deﬁned as an adequate specimen for histological diag-
nosis.  The tissue collection rate is deﬁned as the 
proportion of the number of adequate specimens to the 
number of randomized patients in each arm.  All sta-
tistical analyses will be conducted using JMP soft-
ware (ver. 11; SAS Institute,  Cary,  NC,  USA).
　 It has been reported that the tissue collection rate 
for histological diagnosis by using a conventional 
22-gauge needle in pancreatic masses is 62.5  [10].  
We estimate a 20  increase of the tissue collection 
rate by using EUS Sonopsy CY® in the retrospective 
study in our hospital.  Based on this,  a sample size of 
200 patients is calculated with a power of 0.8 and a 
2-sided alpha of 0.05.
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